Trial Profile
Multicenter Randomized Trial Evaluating FOLFIRI Plus Cetuximab Versus FOLFIRI Plus Bevacizumab in First Line Treatment of Metastatic Colorectal Cancer
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 28 Feb 2024
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary) ; Bevacizumab; Fluorouracil; Folinic acid; Irinotecan
- Indications Adenocarcinoma; Colon cancer; Colorectal cancer; Rectal cancer
- Focus Therapeutic Use
- Acronyms FIRE-3
- 20 Jan 2024 Results of pooled analysis from TRIBE , FIRE-3 and MAVERICC ; investigating the effect of myostatin/activin pathway gene expression and SNPs in mCRC patients, presented at the 2024 Gastrointestinal Cancers Symposium
- 20 Jan 2024 Results assessing Refining first-line treatment decision in RAS wildtype metastatic colorectal cancer by combining clinical biomarkers presented at the 2024 Gastrointestinal Cancers Symposium
- 06 Jun 2023 Results assessing the effect of genetic variants in MHC class I and II pathways on first-line treatment outcome in mCRC patients presented at the 59th Annual Meeting of the American Society of Clinical Oncology.